Clinical Trial Update: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating multiple dose regimens of MT-3724 with lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma; study terminated with posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• MT-3724

Snippet

Sponsor: Molecular Templates, Inc. | Conditions: Non-hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2022-08-16